EMILY HOLLOWAY: Open Payments
NPI 1790404952 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$954 in 10 payments from 9 companies in 2025. Trend: 2023 $417 · 2024 $690 · 2025 $954
Food & beverage: $954
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $258 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 1 | $123 |
| Phathom Pharmaceuticals, Inc. | 1 | $122 |
| ABBVIE INC. | 1 | $103 |
| Medtronic, Inc. | 1 | $93 |
| Supernus Pharmaceuticals, Inc. | 1 | $92 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
Products named: CAPLYTA, Auvelity, REXULTI, VOQUEZNA, QULIPTA, INTELLIS ADAPTIVESTIM, Qelbree, XIFAXAN.
Industry payments across MS — which companies pay providers there.
